

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Fenflor 300 mg/ml solution for injection for pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Florfenicol 300 mg

Excipients:

Qualitative composition of excipients and other constituents
Dimethyl sulfoxide
Propylene glycol
Macrogol 400

A light yellow to yellow, clear, viscous liquid.

3. CLINICAL INFORMATION

3.1 Target species

Pigs.

3.2 Indications for use for each target species

Treatment of acute outbreaks of respiratory disease caused by strains of *Actinobacillus pleuropneumoniae* and *Pasteurella multocida* susceptible to florfenicol.

3.3 Contraindications

Do not use in boars intended for breeding.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of known resistance to the active substance.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Wipe the stopper before removing each dose. Use a dry, sterile syringe and needle.

Do not use in piglets of less than 2 kg.

The product should be used in conjunction with susceptibility testing and take into account official and local antimicrobial policies.

Use a suitable draw-off needle or automatic dosing syringe to avoid excessive puncturing of the closure.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Care should be taken to avoid accidental self-injection.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

People with known hypersensitivity to florfenicol, propylene glycol and polyethylene glycols should avoid contact with the veterinary medicinal product.

In case of accidental contact with eyes, rinse immediately with plenty of water.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Pigs:

Common (1 to 10 animals / 100 animals treated):	Diarrhoea ¹ Peri-anal and rectal erythema/oedema ¹
Undetermined frequency (cannot be estimated from the available data):	Injection site swelling ² Injection site inflammation ³

¹May affect up to 50% of the animals; can be observed for one week.

²May last up to 5 days.

³May last up to 28 days.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Studies in laboratory animals have not revealed any evidence of embryo- or foeto-toxic potential for florfenicol. However, the safety of the product in sows has not been established during pregnancy and lactation.

The use is not recommended during pregnancy and lactation.

Fertility:

Do not use in boars intended for breeding.

3.8 Interaction with other medicinal products and other forms of interaction

No data available.

3.9 Administration routes and dosage

Intramuscular use.

15 mg/kg bodyweight (1 ml per 20 kg) by intramuscular injection into the neck muscle twice at 48 hour intervals using a dry, sterile 16-gauge needle.

The volume administered per injection site should not exceed 3 ml.

To ensure a correct dosage, body weight should be determined as accurately as possible.

It is recommended to treat animals in the early stages of disease and to evaluate the response to treatment within 48 hours after the second injection.

If clinical signs of respiratory disease persist 48 hours after the last injection, treatment should be changed using another formulation or another antibiotic and continued until clinical signs have resolved.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

In swine after administration of 3 times the recommended dose or more a reduction in feeding, hydration and weight gain has been observed.

After administration of 5 times the recommended dose or more vomiting has also been noted.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Meat and offal: 18 days.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QJ01BA90

4.2 Pharmacodynamics

Florfenicol is a broad-spectrum synthetic antibiotic active against most Gram-positive and Gram-negative bacteria isolated from domestic animals. Florfenicol acts by inhibition of protein synthesis at the ribosomal level and is bacteriostatic. However, bactericidal activity has been demonstrated *in-vitro* against *Actinobacillus pleuropneumoniae* and *Pasteurella multocida*.

In-vitro testing has shown that florfenicol is active against the bacterial pathogens most commonly isolated in respiratory diseases in pigs, including *Actinobacillus pleuropneumoniae* and *Pasteurella multocida*.

Acquired resistance to florfenicol is mediated by efflux pump resistance associated with a *floR* gene. In target pathogens, such resistance has only been identified in *Pasteurella multocida*. Cross resistance with chloramphenicol can occur.

4.3 Pharmacokinetics

After a single intramuscular administration of the recommended dose of 15 mg/kg maximum plasma concentrations of 2.08 µg/ml were reached after 2 hours.

The harmonic mean elimination half life was 10.37 hours.

After administration to pigs by the intramuscular route, florfenicol is rapidly excreted, primarily in urine. The florfenicol is extensively metabolised.

Serum concentrations persist above 1 µg/ml for 12 to 24 hours following IM administration. Florfenicol concentrations achieved in lung tissue reflect plasma concentrations, with a lung: plasma concentration ratio of approximately 1.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 28 days.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

50, 100 and 250 ml Type I amber glass bottle closed with a bromobutyl rubber stopper and aluminium seal.

1 bottle (50 ml) in cardboard box.
1 bottle (100 ml) in cardboard box.
1 bottle (250 ml) in cardboard box.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA, d.d., Novo mesto

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

Date of first authorisation:

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARDBOARD BOX

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Fenflor 300 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Florfenicol 300 mg/ml

3. PACKAGE SIZE

50 ml

100 ml

250 ml

4. TARGET SPECIES

Pigs



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Intramuscular use

7. WITHDRAWAL PERIODS

Withdrawal period:

Meat and offal: 18 days

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached, use within 28 days.

Once broached, use by: ...

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA

14. MARKETING AUTHORISATION NUMBERS

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

LABEL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Fenflor 300 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Florfenicol 300 mg/ml

50 ml

100 ml

250 ml

3. TARGET SPECIES

Pigs



4. ROUTES OF ADMINISTRATION

Intramuscular use

5. WITHDRAWAL PERIODS

Withdrawal period:

Meat and offal: 18 days

6. EXPIRY DATE

Exp. {mm/yyyy}

Once broached, use within 28 days.

Once broached, use by: ...

7. SPECIAL STORAGE PRECAUTIONS

8. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA

9. BATCH NUMBER

Lot {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Fenflor 300 mg/ml solution for injection for pigs

2. Composition

Each ml contains:

Active substance:

Florfenicol 300 mg

A light yellow to yellow, clear, viscous liquid.

3. Target species

Pigs.



4. Indications for use

Treatment of acute outbreaks of respiratory disease caused by strains of *Actinobacillus pleuropneumoniae* and *Pasteurella multocida* susceptible to florfenicol.

5. Contraindications

Do not use in boars intended for breeding.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of known resistance to the active substance.

6. Special warnings

Special warnings:

None.

Special precautions for safe use in the target species:

Wipe the stopper before removing each dose. Use a dry, sterile syringe and needle.

Do not use in piglets of less than 2 kg.

The product should be used in conjunction with susceptibility testing and take into account official and local antimicrobial policies.

Use a suitable draw-off needle or automatic dosing syringe to avoid excessive puncturing of the closure.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Care should be taken to avoid accidental self-injection.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

People with known hypersensitivity to florfenicol, propylene glycol and polyethylene glycols should avoid contact with the veterinary medicinal product.

In case of accidental contact with eyes, rinse immediately with plenty of water.

Pregnancy and lactation:

Studies in laboratory animals have not revealed any evidence of embryo- or foeto-toxic potential for florfenicol. However, the safety of the product in sows has not been established during pregnancy and lactation.

The use is not recommended during pregnancy and lactation.

Fertility:

Do not use in boars intended for breeding.

Interaction with other medicinal products and other forms of interaction:

No data available.

Overdose:

In swine after administration of 3 times the recommended dose or more a reduction in feeding, hydration and weight gain has been observed.

After administration of 5 times the recommended dose or more vomiting has also been noted.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Pigs:

Common (1 to 10 animals / 100 animals treated):	Diarrhoea ¹ Peri-anal and rectal erythema/oedema ¹
Undetermined frequency (cannot be estimated from the available data):	Injection site swelling ² Injection site inflammation ³

¹May affect up to 50% of the animals; can be observed for one week.

²May last up to 5 days.

³May last up to 28 days.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Intramuscular use.

15 mg/kg bodyweight (1 ml per 20 kg) by intramuscular injection into the neck muscle twice at 48 hours interval.

It is recommended to treat animals in the early stages of disease and to evaluate the response to treatment within 48 hours after the second injection.

If clinical signs of respiratory disease persist 48 hours after the last injection, treatment should be changed using another formulation or another antibiotic and continued until clinical signs have resolved.

9. Advice on correct administration

To ensure a correct dosage, body weight should be determined as accurately as possible.

The injection should only be given in the neck.

Wipe the stopper before removing each dose. Use a dry, sterile 16-gauge needle.

Not more than 3 ml should be administered at one injection site.

10. Withdrawal periods

Meat and offal: 18 days.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf-life after first opening the immediate packaging: 28 days.

When the container is breached (opened) for the first time, using the in-use shelf-life which is specified on this package insert, the date on which any product remaining in the container should be discarded should be worked out. This discard date should be written in the space provided on the label and carton.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

1 bottle (50 ml) in cardboard box.

1 bottle (100 ml) in cardboard box.

1 bottle (250 ml) in cardboard box.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.